Ensayos Clínicos de Tiroides
Abiertos a Reclutamiento en España

Actualizado marzo 2025

Información Pública obtenida a partir de: Clinical Trials.gov; EU Clinical Trials Register; REEC (AEMPS)

Para iniciar la búsqueda, teclee el texto en la barra a continuación.

EudraCT-NumberNCTSTUDY-CodeTITLEPhaseINDICATIÓNSTATUSMEDICACIÓNSITESSPONSOR
2024-512606-25-003093116TPX-0005-01A Study of Repotrectinib (TPX-0005)
in Patients With Advance Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Phase I / IIPhase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.RECRUITINGOral repotrectinib (TPX-0005)H. Vall d´Hebron (BCN)
F. Jimenez Diaz (Madrid)
H. 12 de Octubre (Madrid)
H.U. Sanchinarro (Madrid)
I. Oncologico de Valencia
H. Quiron de Xeus (BCN)
M.D. Anderson (Madrid)
CUN
Turning Point Therapeutics, Inc.
2022-501253-37-0026280673475-158A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158)Phase IIThyroid Carcinoma
Salivary Gland Carcinoma (sarcomas and mesenchymal tumors are excluded)
RECRUITINGPembrolizumabH.U. Vall d´Hebron (Barcelona)
H.U. Ramón y Cajal (Madrid)
H.U. 12 de Octubre (Madrid)
H. V. de la Victoria (Málaga)
Merck Sharp & Dohme Corp
2023-504898-20-006235216GETNE T2318 A Multicenter, Open Label, Two Cohort, Single Arm, Phase II Study to Evaluate the Efficacy and Safety of the Anti-TROP2 Antibody-drug Conjugate Sacituzumab Govitecan in Patients With Advanced Differentiated and Anaplastic Thyroid Neoplasms.Phase IISETHY is a prospective, multicohort, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory differentiated thyroid carcinoma (DTC) or anaplastic thyroid carcinoma (ATC).

The main hypothesis is that treatment with sacituzumab govitecan, a anti-Trophoblast cell surface antigen 2 (TROP-2), could be an effective treatment option for patients with either differentiated and anaplastic thyroid neoplasms because TROP-2 is highly expressed at the membrane of DTC and ATC.
RECLUTANDOSacituzumab govitecan11 SitesGrupo Espanol de Tumores Neuroendocrinos
2023-507418-28-004589845BO41932Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform TrialPhase IITreatment will be assigned on the basis of relevant oncogenotype, will have cohort-specific inclusion/exclusion criteria, and, unless otherwise specified, will continue until disease progression, loss of clinical benefit, unacceptable toxicity, participant or physician decision to discontinue, or death, whichever occurs first.RECRUITINGPralsetinib
Entrectinib
Belvarafenib
H. Vall d´Hebron (BCN)
C.U.N (Navarra)
Start-F.J. Diaz (Madrid)
Start-Sanchinarro
H. 12 de Octubre (Madrid)
H.La Paz (Madrid)
H. la Fe (Valencia)
Hoffmann-La Roche
2024-514542-37-003175224APL-101-01APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors (SPARTA)Phase IIPhase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors. Include Thyroid Cancer Cohort.RECRUITINGAPL-101 Oral Capsules11 SitesApollomics Inc.
2022-000627-205503797F8394-201A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF AlterationsPhase IIThe objective of this study is to evaluate the efficacy of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with rare solid tumors, melanoma, thyroid, or recurrent primary CNS tumors harboring BRAF V600E mutation. This will be conducted as four open-label subprotocols (F8394-201A; F8394-201B; F8394-201C; F8394-201D) under one master protocol.RECRUITINGPlixorafenib
Cobicistat
H.U. Vall'Hebron
H.U. 12 Octubre
H.U. Santiago Compostela
H.U. Virgen Rocio
H. Clinico de Valencia
Fore Biotherapeutics
UNK6837090SPAINTRKRetrospective Analysis of the Experience with Larotrectinib in Patients with Solid Neoplasms with NTRK Fusion in Spain (SPAINTRK)RetrospectiveThis is an observational retrospective study including thyroid cancer patients with solid neoplasms with NTRK fusions.RECRUITINGNA14 SitesGrupo Espanol de Tumores Neuroendocrinos

Puede seleccionar el número de filas a representar entre: 4, 8 o 10